Strides Pharma Science lit up the charts on Thursday, with its share price surging over 9% after the company announced that OneSource Specialty Pharma Ltd. received final listing and trading approval. The stock climbed to ₹637.25 on the BSE, a jump of 9.55%, as investors cheered the development. Starting January 24, OneSource will make its debut on both the NSE and BSE, marking a significant milestone in Strides Pharma’s restructuring journey. The spotlight is on Strides’ decision to demerge its Contract Development and Manufacturing Organization (CDMO) business into OneSource, a move approved by the National Company Law Tribunal (NCLT) in 2024. This demerger, part of a broader strategy to unlock value, included separating the oral soft gelatin business and rebranding the CDMO unit as OneSource. Shareholders of Strides benefitted from the arrangement, receiving one equity share in OneSource for every two held in Strides, with the record date for this allocation set at December 6, 2024. By the end of the process, Strides shareholders collectively owned 44% of OneSource. The broader picture for Strides Pharma has been mixed. Over the past month, the stock has dropped more than 10%, and it’s down 16% over three months. Yet, the long-term story remains strong. The stock has delivered stellar returns of 100% over the past year and nearly 290% over two years, cementing its status as a multibagger.